Genprex announces $2.7M registered direct offering plus warrants for up to $5.4M; Nasdaq compliance risk remains

Genprex, Inc.

Issued 243,622 shares at $11.21/sh for ~$2.7M gross proceeds; net ~$2.3M after fees.
Concurrent private placement of warrants to purchase up to 487,244 shares at $11.00/sh, exercisable for 24 months.
Company still at risk of Nasdaq delisting; reverse stock split (1:50) implemented Oct 21, 2025; exception expires Oct 31, 2025.
Proceeds to be used for working capital and general corporate purposes.
H.C. Wainwright acting as placement agent; fees 7% cash plus warrants.

Key facts

Extracted from this filing and checked against the source text.

Equity Issuances SEC 8-K Item 3.02/3.03 confidence 0.9

Genprex, Inc. issued up to an aggregate of 487,244 shares of Common Stock of warrant to certain investors named in the Purchase Agreement.

Security: warrant
Shares: up to an aggregate of 487,244 shares of Common Stock
Purchaser: certain investors named in the Purchase Agreement

Exact text from the filing

the Company agreed to issue to the Purchasers warrants (the “Private Warrants”) exercisable for up to an aggregate of 487,244 shares of Common Stock (the “Private Warrant Shares”)

View on SEC.gov

52 equity issuances filed in the last 30 days. Browse all equity issuances →

Genprex, Inc. filing history →

Source: SEC EDGAR

accession 0001437749-25-031678

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.